Black Rock Inc. Biovie Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Biovie Inc. stock. As of the latest transaction made, Black Rock Inc. holds 21,172 shares of BIVI stock, worth $58,646. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,172

Previous 327,930 93.54%

Holding current value

$58,646

Previous $173,000 95.38%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.4 - $0.56 $122,703 - $171,784	-306,758 Reduced 93.54%	21,172 $8,000
Q1 2024 May 10, 2024	SELL	$0.53 - $1.89 $11,949 - $42,611	-22,546 Reduced 6.43%	327,930 $173,000
Q4 2023 Feb 13, 2024	BUY	$1.22 - $5.24 $340,083 - $1.46 Million	278,757 Added 388.68%	350,476 $441,000
Q3 2023 Nov 13, 2023	SELL	$2.75 - $5.17 $57,370 - $107,856	-20,862 Reduced 22.53%	71,719 $244,000
Q2 2023 Aug 11, 2023	BUY	$4.09 - $8.29 $199,444 - $404,253	48,764 Added 111.29%	92,581 $399,000
Q1 2023 May 12, 2023	BUY	$4.89 - $10.53 $43,291 - $93,222	8,853 Added 25.32%	43,817 $354,000
Q4 2022 Feb 13, 2023	BUY	$3.86 - $42.0 $99,746 - $1.09 Million	25,841 Added 283.25%	34,964 $271,000
Q3 2022 Nov 14, 2022	SELL	$1.38 - $25.6 $365 - $6,784	-265 Reduced 2.82%	9,123 $22,000
Q2 2022 Aug 12, 2022	SELL	$1.44 - $5.04 $228 - $801	-159 Reduced 1.67%	9,388 $14,000
Q1 2022 May 12, 2022	SELL	$2.74 - $5.65 $1,306 - $2,695	-477 Reduced 4.76%	9,547 $45,000
Q4 2021 Feb 10, 2022	BUY	$4.41 - $6.99 $16,056 - $25,450	3,641 Added 57.04%	10,024 $45,000
Q3 2021 Nov 09, 2021	SELL	$6.69 - $16.93 $909 - $2,302	-136 Reduced 2.09%	6,383 $42,000
Q2 2021 Aug 11, 2021	BUY	$10.57 - $21.61 $68,905 - $140,875	6,519 New	6,519 $111,000

Others Institutions Holding BIVI

# of Institutions

Shares Held

4.73M

Call Options Held

17.2K

Put Options Held

27K

View Full List

About BIOVIE INC.

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $83.6M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

More about BIVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account